Perkinelmer (PKI)

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, the company delivers unique solutions to serve the diagnostics, life sciences, food, and applied markets. IT strategically partners with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Its dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index.

Company profile

Prahlad Singh
Fiscal year end
Former names
2Cure, LLC • BioLegend CNS, Inc. • BioLegend Ventures, LLC • BioLegend, Inc. • Caliper Life Sciences, Inc. • Cambridge Research • Dharmacon, Inc. • Horizon Discovery, Inc. • Immunodiagnostic Systems Inc. • Nexcelom Bioscience Holdings, LLC ...
IRS number

PKI stock data

Investment data

Data from SEC filings
Securities sold
Number of investors


10 May 22
12 Aug 22
29 Dec 22
Quarter (USD) Apr 22 Jan 22 Oct 21 Jul 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Jan 22 Jan 21 Dec 19 Dec 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 670.75M 670.75M 670.75M 670.75M 670.75M 670.75M
Cash burn (monthly) (no burn) 26.64M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) n/a 114.65M n/a n/a n/a n/a
Cash remaining n/a 556.1M n/a n/a n/a n/a
Runway (months of cash) n/a 20.9 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Aug 22 Okun Andrew Common Stock Sell Dispose S No Yes 164.37 2,538 417.17K 6,391
1 Aug 22 Okun Andrew Common Stock Sell Dispose S No Yes 169.6 635 107.7K 8,929
22 Jul 22 Tereau Daniel R Common Stock Sell Dispose S No Yes 145.14 5,700 827.3K 13,380
22 Jul 22 Tereau Daniel R Common Stock Option exercise Acquire M No No 52.65 5,700 300.11K 19,080
22 Jul 22 Tereau Daniel R NQ Stock Option Common Stock Option exercise Dispose M No No 52.65 5,700 300.11K 3,750
24 Jun 22 Mock James M Common Stock Sell Dispose S No Yes 146.34 663 97.02K 27,577
24 Jun 22 Mock James M Common Stock Sell Dispose S No Yes 145.78 2,290 333.84K 28,240
24 Jun 22 Mock James M Common Stock Sell Dispose S No Yes 144.9 2,072 300.23K 30,530
6 May 22 Witz Pascale Common Stock Grant Acquire A No No 0 744 0 7,360
6 May 22 Witz Pascale Common Stock Grant Acquire A No No 0 610 0 6,616
86.1% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 624 639 -2.3%
Opened positions 67 111 -39.6%
Closed positions 82 71 +15.5%
Increased positions 199 224 -11.2%
Reduced positions 239 190 +25.8%
13F shares Current Prev Q Change
Total value 18.95B 21.77B -13.0%
Total shares 108.63M 108.3M +0.3%
Total puts 239.9K 130.9K +83.3%
Total calls 268.4K 226.9K +18.3%
Total put/call ratio 0.9 0.6 +54.9%
Largest owners Shares Value Change
TROW T. Rowe Price 14.95M $2.61B +48.6%
Capital Research Global Investors 14.32M $2.5B +9.4%
Vanguard 13.72M $2.39B -0.5%
BLK Blackrock 8.43M $1.47B +0.5%
Select Equity 5.73M $999.86M -7.9%
STT State Street 5.16M $899.64M +1.8%
Massachusetts Financial Services 4.18M $728.57M +1.5%
Pictet Asset Management 3.54M $617.76M +5.0%
Geode Capital Management 2.43M $423.82M +4.3%
JHG Janus Henderson 2.25M $392.92M +1.2%
Largest transactions Shares Bought/sold Change
TROW T. Rowe Price 14.95M +4.89M +48.6%
Capital Research Global Investors 14.32M +1.24M +9.4%
Norges Bank 0 -1.23M EXIT
GS Goldman Sachs 928.55K -972.41K -51.2%
JPM JPMorgan Chase & Co. 297.09K -541.8K -64.6%
Select Equity 5.73M -491.52K -7.9%
Echo Street Capital Management 688.59K -395.57K -36.5%
Ceredex Value Advisors 0 -340.84K EXIT
Alliancebernstein 1.11M +339.45K +44.2%
Lord, Abbett & Co. 0 -245.4K EXIT

Financial report summary

  • If the markets into which we sell our products decline or do not grow as anticipated due to a decline in general economic conditions, or there are uncertainties surrounding the approval of government or industrial funding proposals, or there are unfavorable changes in government regulations, we may see an adverse effect on the results of our business operations.
  • Our growth is subject to global economic and political conditions, and operational disruptions at our facilities.
  • If we do not introduce new products in a timely manner, we may lose market share and be unable to achieve revenue growth targets.
  • We may not be able to successfully execute acquisitions or divestitures, license technologies, integrate acquired businesses or licensed technologies into our existing businesses, or make acquired businesses or licensed technologies profitable.
  • If we do not compete effectively, our business will be harmed.
  • Our quarterly operating results could be subject to significant fluctuation, and we may not be able to adjust our operations to effectively address changes we do not anticipate, which could increase the volatility of our stock price and potentially cause losses to our shareholders.
  • A significant disruption in third-party package delivery and import/export services, or significant increases in prices for those services, could interfere with our ability to ship products, increase our costs and lower our profitability.
  • Disruptions in the supply of raw materials, certain key components and other goods from our limited or single source suppliers could have an adverse effect on the results of our business operations, and could damage our relationships with customers.
  • If we do not retain our key personnel, our ability to execute our business strategy will be limited.
  • If we experience a significant disruption in, or breach in security of, our information technology systems or those of our customers, suppliers or other third parties, or cybercrime, resulting in inappropriate access to or inadvertent transfer of information or assets, or if we fail to implement new systems, software and technologies successfully, our business could be adversely affected.
  • We may not be successful in adequately protecting our intellectual property.
  • If we are unable to renew our licenses or otherwise lose our licensed rights, we may have to stop selling products or we may lose competitive advantage.
  • The manufacture and sale of products and services may expose us to product and other liability claims for which we could have substantial liability.
  • If we fail to maintain satisfactory compliance with the regulations of the United States Food and Drug Administration and other governmental agencies in the United States and abroad, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil, criminal or monetary penalties.
  • Changes in governmental regulations may reduce demand for our products or increase our expenses.
  • The healthcare industry is highly regulated and if we fail to comply with its extensive system of laws and regulations, we could suffer fines and penalties or be required to make significant changes to our operations which could have a significant adverse effect on the results of our business operations.
  • Economic, political and other risks associated with foreign operations could adversely affect our international sales and profitability.
  • We have a substantial amount of outstanding debt, which could impact our ability to obtain future financing and limit our ability to make other expenditures in the conduct of our business.
  • Restrictions in our senior unsecured revolving credit facility and other debt instruments may limit our activities.
  • Discontinuation, reform, or replacement of LIBOR may adversely affect our variable rate debt.
  • Our share price will fluctuate.
  • Dividends on our common stock could be reduced or eliminated in the future.
Management Discussion
  • Our overall revenue in the first quarter of fiscal year 2022 was $1,259.4 million which decreased by $48.2 million, or 4%, as compared to the first quarter of fiscal year 2021, reflecting a decrease of $196.0 million, or 23%, in our Diagnostics segment revenue offset by an increase of $147.8 million, or 33%, in our Discovery & Analytical Solutions segment revenue. The decrease in our Diagnostics segment revenue for the first quarter of fiscal year 2022 was driven by a decrease in revenue from our COVID-19 product offerings of $239.7 million, which was partially offset by increase in revenue across our core portfolio of $43.7 million. Additionally, due to the decrease in COVID-19 cases and related decreased need for COVID-19 testing, the California Department of Public Health ("CDPH") notified us on March 31, 2022 that it intends to end its contract with us for the supply and operation of the Valencia Branch Laboratory effective on May 15, 2022. We shall recognize the unamortized contract liability pertaining to the nonrefundable prepayment as revenue over the remaining period through May 15, 2022. The increase in our Discovery & Analytical Solutions segment revenue for the first quarter of fiscal year 2022 was driven by an increase in our life sciences market and applied markets revenue, partially offset by unfavorable changes in foreign exchange rates. The increase in our life sciences market revenue was the result of an increase in revenue from businesses acquired in fiscal year 2021 along with organic growth in our pharmaceutical and biotechnology markets. The increase in our applied markets revenue was driven by increased demand from our industrial and food markets, which were partially offset by decreased demand from our environmental market.

Content analysis

H.S. sophomore Avg
New words: Branch, CDPH, Department, energy, fall, nonrefundable, notified, organic, pertaining, preclude, prepayment, refinance, Renminbi, repatriated, repatriating, repay, retire, Russian, strong, tender, Ukraine, undistributed, Valencia, war
Removed: academia, accounted, actuarial, amortized, amplified, ASC, assuming, ASU, bearing, Cambridge, charge, China, closure, cloud, commensurate, complexity, Conversely, disposition, entity, Euribor, execution, expedient, FASB, force, format, fourth, franchise, geographic, governing, greater, Horizon, immaterial, indefinite, indenture, Indian, initially, installation, instrument, interim, intraperiod, investor, liquidation, mature, matured, member, mentioned, methodology, modified, mortality, nearest, noncancelable, November, obtaining, offering, option, original, ownership, practical, produced, prospectively, rational, recoverability, redeemed, redemption, registered, released, relief, retained, retrospective, retrospectively, royalty, Rupee, separate, Simplifying, specifically, spot, spread, standing, subsidiary, sum, Sunday, surrender, sustainability, swap, systematic, tested, thereon, Topic, Tulip, unpaid, unsatisfied, week


Methods and compositions for improving removal of ribosomal RNA from biological samples
2 Aug 22
The invention generally relates to compositions for maximizing capture of affinity-labeled molecules on solid supports.
PDMS Granular Coated Vial
28 Jul 22
The present invention is a system and method for improving extraction of analytes from a solution by disposing a plurality of polydimethylsiloxane(PDMS) particles in a thin layer on an inner wall of an extraction vial, by increasing a surface area and volume of particles disposed to extract analytes from the solution and thereby increasing extraction capacity and speed for gas chromatography-mass spectrometry (GC-MS) analysis.
Method of detecting presences of different antinuclear antibody fluorescence pattern types without counterstaining and apparatus therefor
21 Jul 22
A method and apparatus are provided for detecting respective potential presences of respective different cellular fluorescence pattern types on a biological cellular substrate including human epithelioma cells (HEp cells), wherein the fluorescence pattern types include different antinuclear antibody fluorescence pattern types.
Finger-Tight Gas Chromatograph (GC) Column Connections
21 Jul 22
A gas chromatograph (GC) column connection device includes a housing including first and second opposite ends, the housing including a housing bore extending therethrough between the first and second ends of the housing.
Systems and Methods for Emulating Scintillation Events Using an Electronic Test Source
21 Jul 22
Presented herein are systems and methods that provide for calibration and/or testing of liquid scintillation counters (LSCs) using an electronic test source.